新里程(002219) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter of 2024 was RMB 860.51 million, a decrease of 4.43% year-over-year[3] - Net profit attributable to shareholders for the third quarter was RMB -7.35 million, an improvement of 68.84% year-over-year[3] - Total revenue for the period reached 2,680,748,437.88 RMB, an increase from 2,507,074,501.01 RMB in the previous period[19] - Operating profit for the period was 74,974,123.46 RMB, up from 41,224,104.30 RMB in the previous period[22] - Net profit for the period was 56,491,361.49 RMB, compared to 36,231,423.01 RMB in the previous period[22] - Net profit attributable to parent company shareholders increased to 52,794,403.83 from 33,418,091.37, showing significant growth[24] - Comprehensive income total rose to 56,491,361.49 from 36,231,423.01, indicating overall financial improvement[24] - Basic and diluted earnings per share both increased to 0.0155 from 0.0100, reflecting higher profitability[24] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 6.18 billion, an increase of 1.67% compared to the end of the previous year[3] - The company's equity attributable to shareholders increased by 5.35% to RMB 2.31 billion compared to the end of the previous year[3] - Total assets increased from RMB 6,080,204,990.53 at the beginning of the period to RMB 6,181,836,361.04 at the end of the period[17] - Total liabilities decreased slightly to 3,827,256,953.63 RMB from 3,845,698,741.33 RMB[18] - Total equity increased to 2,354,579,407.41 RMB from 2,234,506,249.20 RMB[18] - The company's accounts receivable increased from RMB 1,023,067,107.20 at the beginning of the period to RMB 1,138,802,108.35 at the end of the period[17] - The company's short-term borrowings increased from RMB 716,486,474.08 at the beginning of the period to RMB 768,919,420.76 at the end of the period[17] - The company's accounts payable increased from RMB 1,299,581,146.42 at the beginning of the period to RMB 1,376,434,469.67 at the end of the period[17] Cash Flow - Operating cash flow for the first nine months of 2024 was RMB 182.33 million, an increase of 1.68% year-over-year[3] - Cash received from sales of goods and services increased to 2,640,473,369.46 from 2,351,494,251.04, showing higher revenue generation[24] - Net cash flow from operating activities slightly increased to 182,332,848.56 from 179,311,770.70, indicating stable operational performance[26] - Cash paid for goods and services increased to 1,067,617,179.59 from 1,011,576,344.16, reflecting higher operational expenses[26] - Cash paid to employees increased to 817,701,013.62 from 797,093,862.36, showing higher labor costs[26] - Net cash flow from investing activities decreased to -248,129,070.99 from -249,957,842.42, indicating reduced investment outflows[26] - Net cash flow from financing activities turned negative to -169,193,739.50 from 104,954,507.18, reflecting higher debt repayments[27] - Ending cash and cash equivalents decreased to 322,031,481.64 from 572,507,320.47, showing a significant reduction in liquidity[27] Shareholder Information - Beijing New Journey Health Industry Group Co., Ltd. holds 24.23% of shares, totaling 825,927,323 shares[9] - Que Wenbin, an individual shareholder, holds 10.75% of shares, totaling 366,317,769 shares[9] - The company plans to repurchase shares using self-owned or raised funds, with a total amount ranging from RMB 50 million to RMB 100 million, at a price not exceeding RMB 2.74 per share, aiming to repurchase approximately 18,248,175 to 36,496,350 shares, accounting for 0.54% to 1.07% of the total issued shares[13] - As of September 30, 2024, the company has repurchased 5,607,000 shares, representing 0.1645% of the total shares, with a total transaction amount of RMB 10,017,709[13] - On October 21, 2024, the company repurchased an additional 4,320,000 shares, accounting for 0.1267% of the total shares, with a total transaction amount of RMB 10,662,758[13] - As of the report date, the cumulative repurchased shares amount to 9,927,000, representing 0.2913% of the total shares, with a total transaction amount of RMB 20,680,467[13] Expenses and Income - Non-recurring gains and losses for the third quarter amounted to RMB 3.42 million, primarily due to government subsidies and asset disposal losses[4][5] - The company's investment income increased by 235.02% to RMB 2.91 million due to the disposal of equity in affiliated enterprises[6] - Fair value change income was RMB 323,499, a 100% increase due to gains from newly acquired asset management products[7] - Credit impairment loss decreased by RMB 23,683,043.84, a 51.38% improvement due to recovery of previously recognized bad debts[7] - Income tax expense increased by RMB 13,477,005.38, a 297.02% rise due to reduced deferred tax expenses[7] - R&D expenses increased to 7,514,256.13 RMB from 6,905,702.82 RMB[22] - Sales expenses rose to 182,604,597.48 RMB from 140,961,195.18 RMB[22] - Management expenses decreased to 383,700,270.18 RMB from 440,128,431.58 RMB[22] - Financial expenses increased to 92,855,637.61 RMB from 82,996,082.04 RMB[22] - Interest income decreased to 2,578,136.88 RMB from 5,793,685.43 RMB[22] Investments and Loans - Long-term loans decreased by 36.46% to RMB 458.93 million, as some loans were reclassified to current liabilities[6] - Cash received from disposal of subsidiaries and other business units surged by RMB 1,850,521.54, an 86,158.93% increase[7] - Cash paid for acquisition of fixed assets, intangible assets, and other long-term assets increased by RMB 88,537,316.83, a 56.24% rise due to increased investment in Chongzhou Second Hospital's new campus[7] - Cash paid for investments doubled to RMB 3,000,000, a 200% increase from the previous period[7] - Cash received from borrowings decreased by RMB 349,400,000, a 33.39% drop compared to the previous period[7] - Cash paid for debt repayment increased by RMB 363,365,568.12, a 90.32% rise[7] Monetary Funds and Contract Liabilities - The company's monetary funds decreased from RMB 580,235,282.43 at the beginning of the period to RMB 434,651,599.42 at the end of the period[15] - Contract liabilities increased by 39.45% to RMB 4.26 million, reflecting an increase in unfulfilled contract payments[6]